Brenus Pharma Announces its Strategic Committee Supporting & Ensuring Its Value-creating Strategic Plan
BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.
Alongside their CSO & co-founder (B.PINTEUR) and CEO (P.BRAVETTI) this committee reinforces a solid expertise in health tech & pharma industry manufacturing to support the strategic development of the company and anticipate the future of Brenus:
Laurence COMTE ARASSUS: General Manager, GE Healthcare(FBFA zone); Administrator, IHU Ican. Vice President, SNITEM; Board member, GS1 France. Former President, Medtronic France.
Pierre MORGON (Pharm D, LL.M, MBA): CEO, MRGN Advisors; Executive VP, CanSino Biologics; Board chairman and non-Executive director, several biotech.
Hervé GISSEROT: General Manager, CSL Vifor. Former President, LEEM (French Pharma Association) & former CEO, GSK France.
Stéphane LOZE (PharmD): Administrator, Angels Santé; Board Member, SFMPP (French Society of Predictive & Personalized Medicine). Former Head of Strategy & Therapeutic units, Roche France.
“We are delighted to have top renowned healthcare industry executives at our side to challenge and support our strategic plan and are thankful for their trust. As our recent milestones proved it, we have lot of ambition for our STC platform, and our Strategic Committee will help us to deliver it in a value-creating way to optimize our potential and become a leader in Next Gen Immune therapeutics.” said P. Bravetti, CEO.
Brenus initiated a solid internal knowledge thanks to this collaboration between J.GARDETTE, co-Founder and renowned healthcare entrepreneur, former founder at BIOCORP (health-tech company specialized in the design, development, and manufacturing of innovative medical devices) and B.PINTEUR PharmD, co-Founder & CSO, specialized in innovative cellular therapies and former founder of BioElpida(CDMO company specialized in cell therapies’ manufacturing). Joined by P. BRAVETTI PharmD, HEC Paris, CEO, bringing his previous international Large Pharmas experiences (Roche, Servier, Takeda oncology).
Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the resistance mechanisms of tumor cells.
For further information: www.brenus-pharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005664/en/
+ 33 (0)7 87 76 87 72
CONTACT ULYSSE COMMUNICATION
+33 (0)6 87 88 47 26
About Business Wire
24 Martin Lane
EC4R 0DR London
+44 20 7626 1982http://www.businesswire.co.uk
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alveo Technologies Announces ISO 13485:2016 Certification21.3.2023 14:45:00 CET | Press release
Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well™ technology platform, today announced its quality management system (QMS) has achieved ISO 13485:2016 certification for the design, development and manufacture of in vitro diagnostic kits and analyzers for the detection of infectious disease. The globally recognized ISO 13485 standard, published by the International Standards Organization, sets out requirements for establishing and maintaining quality management systems for the medical device industry. Compliance with the ISO 13485 standard is required for companies to market medical devices in many markets, including the European Union, Canada, Japan, and Australia. In addition, the U.S. Food and Drug Administration has announced plans to harmonize its existing medical device QMS requirements with ISO 13485, proposing new regulations that incorporate ISO 13485 as the foundational requirements. “We are thrilled to achieve ISO 13
Wemade Presents ‘ Wateree’s Enhancement Support Event’ to Boost Growth in MIR M21.3.2023 14:00:00 CET | Press release
Wemade's blockbuster MMORPG MIR M: Vanguard and Vagabond (hereinafter "MIR M") is holding the "Wateree’s Enhancement Support" event starting from March 21st, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005487/en/ ‘Wateree’s Enhancement Support Event’ for MIR M starts on March 21, 2023 (Graphic: Wemade) For two weeks, users can participate in two attendance events called "Wateree's Enhancement Support 7 Days Check-in," and "Wateree's Illusory Mystic Realm Support 7 Days Check-in." Simply by checking in, users can obtain abundant rewards such as "Enhancement Stone," "Reforging Stone," "Oil of Blessing," "Illusory Mystic Realm Entry Ticket," and the EXP buff item, "Growth Draught," and more, depending on the number of attendances in the Check-in events. There are also special items available in the in-game Shop for improving crafting and enhancement mastery. The "Wateree's Crafting Mastery Support" package, which
MIR4 Updates ‘Sabuk Clash’ to Determine the Most Powerful Clan21.3.2023 14:00:00 CET | Press release
Wemade’s blockbuster MMORPG MIR4 updated Sabuk Clash, clan vs. clan Castle Siege, on March 21st. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005465/en/ MIR4 Updates ‘Sabuk Clash,’ a tournament style Castle Siege content to determine the Emperor’s Clan, on March 21 (Graphic: Wemade) “Sabuk Clash” is a tournament style Castle Siege content where King’s clans from all servers in each region gather in the Domination Server and fight to become the Emperor’s clan. Only Bicheon Castle King’s clans can participate. The winning clan then becomes the Emperor’s clan, which can collect taxes from the Kings of all servers in each region, adjust individual tax rates per server, and is given authority to manage the Sabuk Castle territory. The first round begins on March 26th at 10 pm, and a new round will be held every week for a total of 3 rounds over 3 weeks. In the first round, a total of 16 clans fight to capture one of the 8
Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm21.3.2023 13:02:00 CET | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA). Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected AAA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005445/en/ Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected AAA. (Photo: Business Wire) “There is an estimated 1.1 million Americans living with an AAA1. Majority of these patients are asymptomatic and many are unaware of their disease until a rupture occurs. This is a catastrophic medical emergency, resulting in over 10,000 deaths each year,” said Philip Batista, MD, Associate Program Director, Vascular and Endovascular Surgery Residency, Cooper. “This algorithm is a powerful ne
José Baselga Research Fund Announces First-Ever Grant to Advance Prion Disease Research21.3.2023 13:02:00 CET | Press release
The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders. JBRF was created by the Baselga family in memory of Dr. José Baselga, a physician-scientist who dedicated his life to the advancement of cancer therapy before passing away two years ago today from Creutzfeldt-Jakob Disease (CJD), an extremely rare, fatal neurodegenerative condition. The Baselga Grant will honor Jose’s legacy and support scientists in the pursuit of understanding, and eradicating, prion diseases such as CJD. “Our family feels incredibly lucky to have had such an amazing father and husband for as long as we did, and we are committed to continuing his legacy of improving people’s lives through innovative medicines,” commented Clara Baselga-Garriga, daughter of José and studen